This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection, respectively, at primary care level.
On 18 September 2023, 13 designated experts from the Western Balkans and Türkiye attended the 12th FWD-Net meeting at the European Chemical Agency (ECHA) in Helsinki, Finland.
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 16-22 July 2023 and includes updates on avian influenza, Echovirus 11, COVID-19, West Nile virus, poliomyelitis, and botulism.
Since April 2023, over 300 shigellosis cases, many with multidrug-resistant Shigella sonnei -infections, have been reported to the European Centre for Disease Prevention and Control (ECDC).